LUNG — Pulmonx Corp

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1127537 ·
Last close
$1.57
Market Cap
$66.31M
52W High
$2.16
52W Low
$1.13
ADV30
507,210
Next earnings
2026-07-29
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 20,586,000 16,044,000 -12,956,000 -13,654,000 119,966,000 61,572,000 74,205,000
Dec 2025 22,598,000 17,541,000 -9,903,000 -10,425,000 129,291,000 69,751,000 75,175,000
Sep 2025 21,502,000 16,052,000 -14,393,000 -13,957,000 138,281,000 76,549,000 78,248,000
Jun 2025 23,859,000 17,204,000 -14,804,000 -15,173,000 147,187,000 75,466,000 78,097,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-29,251,000
Investing CF
$14,160,000
Financing CF
$2,195,000
CapEx
$-160,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-1.30
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-535,212,000
Inventory
$16,310,000
Receivables
$11,271,000
ST Investments
$0
EBIT TTM
$-49,219,000
Pretax Income TTM
$-52,569,000
Interest Exp TTM
$3,350,000
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$88,545,000
EBITDA
$-51,160,000
Free Cash Flow
$-8,362,750
Enterprise Value
$60,188,664
Total Cash
$61,572,000
Total Debt
$56,293,000
Shares Out
42,237,203
Trailing EPS
$-1.30
Book Value
$1.08
ROE
-86.2%
ROA
-24.0%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 90,497,000 -53,663,000 -54,003,000 129,291,000 75,175,000 -32,376,000
Dec 2024 83,789,000 -57,704,000 -56,394,000 162,850,000 77,041,000 -31,537,000
Dec 2023 68,675,000 -61,935,000 -60,843,000 177,781,000 59,466,000 -37,610,000
Dec 2022 53,662,000 -58,637,000 -58,923,000 193,676,000 39,669,000 -45,083,000

TTM Snapshot

Revenues TTM
$64,818,000
NetIncome TTM
$-53,397,000
OpCashFlow TTM
$0
Assets (Latest)
$162,850,000
Forward EPS
$-0.89

Peers — same industry

TickerNameMarket CapLastDaily %
QTI QT IMAGING HOLDINGS, INC. $65.55M $4.95
HCIL Hongchang International Co., Ltd $64.85M $0.12
XTNT Xtant Medical Holdings, Inc. $64.69M $0.46
APT ALPHA PRO TECH LTD $61.81M $6.05
AGPU Axe Compute Inc. $72.00M $6.92

News headlines (Yahoo Finance, 1h cache)

Pulmonx (LUNG) Q1 2026 Earnings Transcript
2026-04-30 16:25 · Yahoo
Pulmonx Corporation Q1 2026 Earnings Call Summary
2026-04-30 12:30 · Yahoo
Pulmonx Corp (LUNG) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic ...
2026-04-30 07:17 · Yahoo
Pulmonx Q1 Earnings Call Highlights
2026-04-29 21:50 · Yahoo
Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates
2026-04-29 21:45 · Yahoo
Pulmonx Reports First Quarter 2026 Financial Results
2026-04-29 20:05 · Yahoo
Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference
2026-04-28 20:05 · Yahoo
How The Pulmonx (LUNG) Investment Narrative Is Resetting Around A Lower Target And Execution Risk
2026-04-19 15:05 · Yahoo
Hims & Hers Health (HIMS) Soars 11.1%: Is Further Upside Left in the Stock?
2026-04-17 10:22 · Yahoo
Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026
2026-04-15 20:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.